A Registered Cohort Study of Inflammatory Demyelination Disease
Sponsor
Ning Wang, MD., PhD. (Other)
Overall Status
Recruiting
CT.gov ID
NCT04386018
Collaborator
(none)
400
1
58.5
6.8
Study Details
Study Description
Brief Summary
This study will provide further insights into the natural course of Inflammatory demyelination disease including clinical features，progression, related antibody spectrum and drug treatment effect
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Registered Cohort Study on Natural Course and Drug Efficacy of Inflammatory Demyelination Disease
Actual Study Start Date
:
May 15, 2020
Anticipated Primary Completion Date
:
Apr 1, 2022
Anticipated Study Completion Date
:
Apr 1, 2025
Outcome Measures
Primary Outcome Measures
- The correlation between clinical phenotypes and Serum antibodies [from date of enrollment until the date of death from any cause,assessed up to 20 years]
Different clinical subtypes of Demyelinating Autoimmune Diseases have different course and prognosis.It may be related to different serum antibodies.
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Outpatient or inpatient
-
Meet the diagnostic criteria of Inflammatory Demyelination Disease.
-
Voluntary participation and informed consent signed by the applicant or his/her family.
Exclusion Criteria:
-
Severe complications
-
Poor prognosis (<1 year survival)
-
Severe mental disorder and inability to cooperate with the examination.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Neurology,First Affiliated Hospital of Fujian Medical University | Fuzhou | Fujian | China | 350005 |
Sponsors and Collaborators
- Ning Wang, MD., PhD.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ning Wang, MD., PhD.,
Director,
First Affiliated Hospital of Fujian Medical University
ClinicalTrials.gov Identifier:
NCT04386018
Other Study ID Numbers:
- MRCTA,ECFAH of FMU [2019]216
First Posted:
May 13, 2020
Last Update Posted:
Nov 13, 2020
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: